AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 252 min read$NRIX

Ring Christine sold $581K of NRIX

Ring Christine (Chief Legal Officer) sold 28,935 shares of Nurix Therapeutics, Inc. (NRIX) at $20.06 ($0.58M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ring Christine
Published Jun 25, 2026, 10:38 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 25, 2026, 10:41 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NRIX
Neutral
medium confidence
Mentioned
$NRIX
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NRIXNeutralLow
01

Why it matters

The disclosed sale totals about $580.5K and is explicitly under a pre-arranged Rule 10b5-1 plan, which typically reduces the inference of new negative information.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the 10b5-1 structure makes it less likely to drive a fundamental repricing.

03

What to watch

The filing provides no information on future trading intent beyond the existence of a pre-arranged plan; without additional context (e.g., multiple concurrent sales), signal quality is limited.

Relevance 4/10Novelty 4/10Timing: Filed same day as the 2026-06-25 sale transaction.

Background

The article is an SEC Form 4 insider transaction for Nurix Therapeutics, Inc. (NRIX) by Ring Christine, Chief Legal Officer.

Company-level read

Ticker impact

$NRIXNeutralMedium confidence
Context

Nurix Therapeutics COO sold 28,935 shares in an open-market transaction at $20.0624 on 2026-06-25 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

Form 4 insider sales are common and the filing explicitly states a pre-arranged 10b5-1 plan, reducing interpretive signal about near-term company outlook.

Market effects

Sector

Minimal; this is company-specific insider transaction data with no sector-wide catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider selling can still coincide with personal liquidity needs rather than bearish fundamentals—so the market may overreact.

Key entities

  • public_company
    Nurix Therapeutics, Inc.

    Issuer of the Form 4 insider sale by its Chief Legal Officer.

  • insider
    Ring Christine

    Chief Legal Officer who sold 28,935 shares at $20.0624/share on 2026-06-25.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NRIX insider trading history →

Related articles

AUG 5
$NRIXMed

Nurix Receives $10M Payment as Sanofi Initiates Phase 1 Trial of STAT6 Degrader SAR448272

Nurix said Sanofi began a Phase 1 first-in-human trial of SAR448272/NX-3911, an oral STAT6 degrader, triggering a $10 million milestone payment. Nurix reported it has received about $139 million from its 2019 Sanofi collaboration and remains eligible for about $453 million in further STAT6-related milestones. Sanofi runs the trial, with U.S. co-development and co-promotion options for Nurix.

clinicaltrialvanguard.com3 min
JUL 9
$NRIXMed

Nurix Therapeutics, Inc. (NRIX): Results of Operations and Financial Condition

Nurix Therapeutics, Inc. (NRIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 nrix-20260709xexx991.htm EX-99.1 Document Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3

SEC EDGAR 8-K6 min
JUN 27
$NRIXMed

Nurix (NRIX) Climbs to 52 - Week High This Deal May Hold the Answer

Nurix Therapeutics (NRIX) extended gains for an eighth straight session, reaching a 52-week high of $23.09 and closing up 16.37% at $22.46, according to trading data cited in the article. The move followed Nurix’s partnership with Roche to co-develop and commercialize bexobrutideg, with $700 million upfront and up to $2.3 billion in milestones, the companies said.

finance.yahoo.com4 min
JUN 10
$INTCMedAI 8/10

Broader Market Settles Higher as Chipmakers Rally

Markets settled higher as inflation expectations eased; the 10-year breakeven rate fell to 2.452%. European yields rose, with Germany’s 10-year Bund at 3.060% (+2.2 bp) and UK gilt at 4.943% (+4.0 bp). Eurozone Sentix confidence improved to -3.4. Chipmakers rallied: Intel +11% after Google ordered 3 million Tensor Processing Units for 2028; others also gained.

finance.yahoo.com7 min